GT Biopharma (GTBP) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $7.03, -4.48% vs the prior close of $7.36.
- Volume 55.23K shares, 0.2x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
GTBP slides 4.5% to $7.03. Closed at $7.03, -4.48% vs the prior close of $7.36. Day range $6.86–$7.32, opened at $7.14.
GTBP daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — GTBP slides 4.5% to $7.03
- Closed at $7.03, -4.48% vs the prior close of $7.36. Day range $6.86–$7.32, opened at $7.14.
- Volume was 55.23K shares, 0.2x its 50-day average of 252.01K — lighter than usual.
- Price is +61.0% vs its 50-day average ($4.37) and +364.4% vs its 200-day average ($1.51).
- 52-week range $0.22–$11.98; today's close sits at 58% of that range, 41.3% below the 52-week high.
Oct 15, 2026 — GTBP jumps 18.5% to $7.36
- Closed at $7.36, +18.52% vs the prior close of $6.21. Day range $6.50–$7.40, opened at $6.50.
- Volume was 63.00K shares, 0.3x its 50-day average of 251.09K — lighter than usual.
- Price is +73.9% vs its 50-day average ($4.23) and +396.2% vs its 200-day average ($1.48).
- 52-week range $0.22–$11.98; today's close sits at 61% of that range, 38.6% below the 52-week high.
Oct 14, 2026 — GTBP slides 4.5% to $6.21
- Closed at $6.21, -4.46% vs the prior close of $6.50. Day range $5.86–$6.44, opened at $6.44.
- Volume was 42.00K shares, 0.2x its 50-day average of 258.64K — lighter than usual.
- Price is +46.2% vs its 50-day average ($4.25) and +328.1% vs its 200-day average ($1.45).
- 52-week range $0.22–$11.98; today's close sits at 51% of that range, 48.2% below the 52-week high.
Oct 13, 2026 — GTBP slides 4.4% to $6.50
- Closed at $6.50, -4.41% vs the prior close of $6.80. Day range $6.33–$7.50, opened at $7.50.
- Volume was 29.50K shares, 0.1x its 50-day average of 270.09K — lighter than usual.
- Price is +57.4% vs its 50-day average ($4.13) and +356.5% vs its 200-day average ($1.42).
- 52-week range $0.22–$11.98; today's close sits at 53% of that range, 45.7% below the 52-week high.
- SEC filings that day: DEF 14A.
Oct 12, 2026 — GTBP rises 1.8% to $6.80
- Closed at $6.80, +1.80% vs the prior close of $6.68. Day range $6.50–$7.05, opened at $6.79.
- Volume was 38.00K shares, 0.1x its 50-day average of 278.49K — lighter than usual.
- Price is +69.7% vs its 50-day average ($4.01) and +387.3% vs its 200-day average ($1.40).
- 52-week range $0.22–$11.98; today's close sits at 56% of that range, 43.2% below the 52-week high.
Oct 9, 2026 — GTBP jumps 12.1% to $6.68
- Closed at $6.68, +12.08% vs the prior close of $5.96. Day range $5.83–$6.68, opened at $5.96.
- Volume was 42.70K shares, 0.2x its 50-day average of 278.16K — lighter than usual.
- Price is +72.3% vs its 50-day average ($3.88) and +389.3% vs its 200-day average ($1.37).
- 52-week range $0.22–$11.98; today's close sits at 55% of that range, 44.2% below the 52-week high.
- SEC filings that day: S-1.
Oct 8, 2026 — GTBP slides 3.9% to $5.96, a 1-month low
- Closed at $5.96, -3.87% vs the prior close of $6.20. Day range $5.80–$6.22, opened at $6.20.
- Volume was 31.50K shares, 0.1x its 50-day average of 286.89K — lighter than usual.
- Price is +53.0% vs its 50-day average ($3.89) and +346.2% vs its 200-day average ($1.34).
- 52-week range $0.22–$11.98; today's close sits at 49% of that range, 50.3% below the 52-week high.
Oct 7, 2026 — GTBP dips 2.7% to $6.20
- Closed at $6.20, -2.67% vs the prior close of $6.37. Day range $6.20–$6.47, opened at $6.30.
- Volume was 18.90K shares, 0.1x its 50-day average of 293.87K — lighter than usual.
- Price is +64.0% vs its 50-day average ($3.78) and +373.4% vs its 200-day average ($1.31).
- 52-week range $0.22–$11.98; today's close sits at 51% of that range, 48.2% below the 52-week high.
Oct 6, 2026 — GTBP jumps 3.4% to $6.37
- Closed at $6.37, +3.41% vs the prior close of $6.16. Day range $6.20–$6.45, opened at $6.31.
- Volume was 22.40K shares, 0.1x its 50-day average of 301.73K — lighter than usual.
- Price is +73.8% vs its 50-day average ($3.66) and +396.9% vs its 200-day average ($1.28).
- 52-week range $0.22–$11.98; today's close sits at 52% of that range, 46.8% below the 52-week high.
Oct 5, 2026 — GTBP rises 1.0% to $6.16
- Closed at $6.16, +0.98% vs the prior close of $6.10. Day range $6.12–$6.68, opened at $6.13.
- Volume was 38.50K shares, 0.1x its 50-day average of 310.93K — lighter than usual.
- Price is +73.9% vs its 50-day average ($3.54) and +391.3% vs its 200-day average ($1.25).
- 52-week range $0.22–$11.98; today's close sits at 51% of that range, 48.6% below the 52-week high.
Oct 2, 2026 — GTBP dips 1.6% to $6.10, 3 down days in a row
- Closed at $6.10, -1.61% vs the prior close of $6.20. Day range $6.00–$6.51, opened at $6.36.
- Volume was 62.10K shares, 0.2x its 50-day average of 319.75K — lighter than usual.
- Price is +78.0% vs its 50-day average ($3.43) and +397.5% vs its 200-day average ($1.23).
- 52-week range $0.22–$11.98; today's close sits at 50% of that range, 49.1% below the 52-week high.
- That makes 3 straight losses.
GTBP latest news & SEC filings
Every SEC filing by or about GTBP in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Oct 9, 2026 · Form S-1 — Registration statement (S-1)
Registration statement (S-1) — registering new shares, usually for an IPO or offering
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 2, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Sep 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
- Item 3.03 — Change to shareholder rights.
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
Sep 15, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
- Item 3.03 — Change to shareholder rights.
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
Sep 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.03 — Change to shareholder rights.
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Aug 14, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$4.52M (prior year -$30.17M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.12 (prior year -$10.92) (loss narrowed vs Jun 30, 2025)
Jul 2, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Things to know before you trade GTBP
- Last results release: Nov 14, 2025 (8-K Item 2.02). Previous ones: Nov 15, 2018, May 10, 2006, May 3, 2005. Based on that rhythm, the next report is likely around Feb 13, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.84% (largest 18.5%). That is a volatile stock.
- Liquidity: about 43.73K shares (≈$307.43K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $7.03 vs a range of $0.22–$11.98 (58% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:25 on Sep 8, 2026
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Sep 25, 2026; 8-K Sep 21, 2026; 8-K Sep 15, 2026.
- Share count: 45.11M shares outstanding (Aug 10, 2026), +1168.0% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
GTBP market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 7.14 | 7.32 | 6.86 | 7.03 | 55.23K |
| Oct 15, 2026 | 6.50 | 7.40 | 6.50 | 7.36 | 63.00K |
| Oct 14, 2026 | 6.44 | 6.44 | 5.86 | 6.21 | 42.00K |
| Oct 13, 2026 | 7.50 | 7.50 | 6.33 | 6.50 | 29.50K |
| Oct 12, 2026 | 6.79 | 7.05 | 6.50 | 6.80 | 38.00K |
| Oct 9, 2026 | 5.96 | 6.68 | 5.83 | 6.68 | 42.70K |
| Oct 8, 2026 | 6.20 | 6.22 | 5.80 | 5.96 | 31.50K |
| Oct 7, 2026 | 6.30 | 6.47 | 6.20 | 6.20 | 18.90K |
| Oct 6, 2026 | 6.31 | 6.45 | 6.20 | 6.37 | 22.40K |
| Oct 5, 2026 | 6.13 | 6.68 | 6.12 | 6.16 | 38.50K |
| Oct 2, 2026 | 6.36 | 6.51 | 6.00 | 6.10 | 62.10K |
| Oct 1, 2026 | 6.34 | 6.46 | 6.00 | 6.20 | 38.70K |
| Sep 30, 2026 | 6.85 | 7.02 | 6.47 | 6.47 | 29.50K |
| Sep 29, 2026 | 7.08 | 7.10 | 6.71 | 6.88 | 34.40K |
| Sep 28, 2026 | 7.00 | 7.25 | 6.79 | 6.80 | 34.90K |
| Sep 25, 2026 | 6.79 | 7.24 | 6.59 | 6.89 | 79.70K |
| Sep 24, 2026 | 7.01 | 7.10 | 6.59 | 6.83 | 28.10K |
| Sep 23, 2026 | 7.08 | 7.28 | 6.82 | 7.10 | 53.70K |
| Sep 22, 2026 | 7.12 | 7.20 | 6.35 | 7.18 | 74.10K |
| Sep 21, 2026 | 7.16 | 7.82 | 6.88 | 7.18 | 57.70K |
About GT Biopharma
GT Biopharma (GTBP) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN FRANCISCO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 109657.
GTBP board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| No Form 3/4/5 filings by this group in the last 12 months. | ||
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| No Form 3/4/5 filings by this group in the last 12 months. | ||
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
GTBP financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-28.35M | -6.68 | $-12.91M |
| Dec 31, 2024 | — | $-13.16M | -6.94 | $-12.90M |
| Dec 31, 2023 | — | $-7.60M | -5.64 | $-8.85M |
| Dec 31, 2022 | — | $-20.88M | -19.66 | $-15.22M |
| Dec 31, 2021 | — | $-58.01M | — | $-15.61M |
Latest balance sheet: total assets $8.11M, total liabilities $1.32M, cash $4.96M (as of Dec 31, 2025).
GTBP earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Nov 14, 2025 | 8-K Item 2.02 (results) | $0.92 |
| Nov 15, 2018 | 8-K Item 2.02 (results) | — |
| May 10, 2006 | 8-K Item 2.02 (results) | — |
| May 3, 2005 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on GTBP
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.